Table 1. First and second line drug resistant frequency among 1893 clinical Mycobacterium tuberculosis isolates, June 2009–June 2011, Xinjiang Uygur Autonomous Region, China.
| Drugs | No. isolates | Rate, % (95% CI) |
| Overall first-line drug resistance | 1117 | 59.0(56.8–61.2) |
| INH | 683 | 36.1(33.9–38.2) |
| RFP | 368 | 19.4(17.7–21.2) |
| SM | 685 | 36.2(34.0–38.4) |
| EMB | 332 | 17.5(15.8–19.3) |
| Overall MDR | 249 | 13.2(11.6–14.7) |
| INH+RFP | 73 | 3.9(3.0–4.7) |
| INH+RFP+SM | 111 | 5.9(4.8–6.9) |
| INH+RFP+EMB | 23 | 1.2(0.7–1.7) |
| INH+RFP+SM+EMB | 42 | 2.2(1.6–2.9) |
| Overall second-line drug resistance | 616 | 32.5(30.4–34.7) |
| FQ | 477 | 25.2(23.2–27.2) |
| AMK | 113 | 6.0(5.0–7.0) |
| CPM | 121 | 6.4(5.3–7.5) |
| KAN | 169 | 8.9(7.6–10.2) |
| PTA | 85 | 4.5(3.6–5.4) |
| Overall pre-XDR | 77 | 30.9(25.1–36.7) |
| FQ | 65 | 26.1(20.6–31.6) |
| AMK | 6 | 2.4(0.5–4.3) |
| CPM | 2 | 0.8* |
| KAN | 4 | 1.6* |
| Overall XDR | 31 | 12.5(8.3–16.6) |
| FQ+AMK | 7 | 2.8(0.7–4.9) |
| FQ+KNA | 10 | 4.0(1.6–6.5) |
| FQ+AMK+CMP | 1 | 0.4* |
| FQ+AMK+KNA | 1 | 0.4* |
| FQ+CMP+KNA | 1 | 0.4* |
| FQ+AMK+CMP+KNA | 4 | 1.6* |
| FQ+AMK(2)/CPM(1)/KNA+PTA | 3 | 1.2* |
| FQ+AMK+CMP/KNA+PTA | 3 | 1.2* |
| FQ+AMK+CMP+KNA+PTA | 1 | 0.4* |
CI, confidence interval; INH, isoniazid; RFP, rifampin, SM, streptomycin, EMB, ethambutol; MDR, multidrug-resistant; FQ, fluoroquinolines (specifically ciprofloxacin, levofloxacin and ciprofloxacin.); AMK, amikacin; CPM, capreomycin; PTA: prothionamid, KAN: kanamycin.
*
95%CI was not determined.